600351 亚宝药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)6.1446.7133.5496.5583.930
总资产报酬率 ROA (%)4.7264.9992.5504.6252.579
投入资产回报率 ROIC (%)5.5415.7892.9265.2513.120

边际利润分析
销售毛利率 (%)54.28557.85455.87561.03059.318
营业利润率 (%)14.6947.7784.5457.3524.893
息税前利润/营业总收入 (%)14.7497.6375.0217.8286.053
净利润/营业总收入 (%)12.1356.1833.8486.6494.188

收益指标分析
经营活动净收益/利润总额(%)92.706131.986142.17888.16672.287
价值变动净收益/利润总额(%)0.079-2.441-3.3217.3782.623
营业外收支净额/利润总额(%)0.312-3.3581.671-0.8060.055

偿债能力分析
流动比率 (X)2.1572.2321.8781.7871.568
速动比率 (X)1.6451.6691.4461.2691.115
资产负债率 (%)23.04622.32527.21927.30429.792
带息债务/全部投入资本 (%)6.4028.60214.20016.253--
股东权益/带息债务 (%)1,426.0741,036.449588.042500.797415.081
股东权益/负债合计 (%)332.472345.935264.142262.957232.322
利息保障倍数 (X)1,650.57168.94012.60314.6555.232

营运能力分析
应收账款周转天数 (天)48.07248.28256.80158.1550.000
存货周转天数 (天)115.645130.818145.597170.2910.000